Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma
About this trial
This is an interventional diagnostic trial for Cervical Adenocarcinoma
Eligibility Criteria
Inclusion Criteria: Diagnosis of carcinoma of the cervix of 1 of the following cellular types: Squamous cell carcinoma Adenocarcinoma Adenosquamous cell carcinoma Stage IB1 disease (no greater than 4 cm) No unequivocal evidence of metastases Adequate surgical candidate No known allergy to triphenylmethane compounds No prior pelvic irradiation No prior retroperitoneal surgery More than 4 weeks since prior cold knife or loop electrosurgical excision procedure (LEEP) cone biopsy Prior cone biopsy allowed provided current disease is stage IB1
Sites / Locations
- Gynecologic Oncology Group
Arms of the Study
Arm 1
Experimental
Diagnostic
Patients receive radiolabeled technetium Tc 99m sulfur colloid injected around the tumor 6 hours prior to or after induction of anesthesia right before surgery. Patients then undergo radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy. Intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held gamma counter.